(AMPH) Amphastar P - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 786m USD | Total Return: -24.8% in 12m

Injectables, Inhalation Aerosols, Nasal Sprays, Insulin APIs
Total Rating 29
Safety 87
Buy Signal -0.64
Drug Manufacturers - Specialty & Generic
Industry Rotation: +3.5
Market Cap: 786M
Avg Turnover: 11.3M
Risk 3d forecast
Volatility43.8%
VaR 5th Pctl7.08%
VaR vs Median-2.40%
Reward TTM
Sharpe Ratio-0.33
Rel. Str. IBD3
Rel. Str. Peer Group1.9
Character TTM
Beta1.373
Beta Downside1.717
Hurst Exponent0.516
Drawdowns 3y
Max DD74.05%
CAGR/Max DD-0.35
CAGR/Mean DD-0.63
EPS (Earnings per Share) EPS (Earnings per Share) of AMPH over the last years for every Quarter: "2021-03": 0.27, "2021-06": 0.21, "2021-09": 0.46, "2021-12": 0.42, "2022-03": 0.47, "2022-06": 0.39, "2022-09": 0.38, "2022-12": 0.73, "2023-03": 0.62, "2023-06": 0.65, "2023-09": 1.15, "2023-12": 0.88, "2024-03": 1.04, "2024-06": 0.94, "2024-09": 0.96, "2024-12": 0.92, "2025-03": 0.74, "2025-06": 0.85, "2025-09": 0.93, "2025-12": 0.73, "2026-03": 0.42,
EPS CAGR: 3.07%
EPS Trend: 19.1%
Last SUE: -3.27
Qual. Beats: -2
Revenue Revenue of AMPH over the last years for every Quarter: 2021-03: 103.02, 2021-06: 101.663, 2021-09: 112.198, 2021-12: 120.887, 2022-03: 120.368, 2022-06: 123.467, 2022-09: 120.129, 2022-12: 135.023, 2023-03: 140.022, 2023-06: 145.712, 2023-09: 180.556, 2023-12: 178.105, 2024-03: 171.836, 2024-06: 182.394, 2024-09: 188.819, 2024-12: 186.523, 2025-03: 170.528, 2025-06: 174.414, 2025-09: 191.84, 2025-12: 183.105, 2026-03: 171.171,
Rev. CAGR: 8.71%
Rev. Trend: 79.3%
Last SUE: -0.36
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: AMPH Amphastar P

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of complex generic and proprietary delivery systems. Its portfolio focuses on injectable, inhalation, and intranasal medications targeting emergency medicine, asthma, and chronic disease management. Key products include BAQSIMI for hypoglycemia, Primatene MIST for asthma, and various emergency syringe treatments.

The company operates a vertically integrated business model, producing its own active pharmaceutical ingredients (APIs), such as recombinant human insulin. This integration is a common strategy in the pharmaceutical sector to mitigate supply chain volatility and maintain higher margins on complex formulations. The high technical barrier to entry for inhalation and intranasal delivery systems often limits competition compared to standard oral solids.

For a deeper look into the companys financial health and valuation metrics, consider reviewing the detailed analysis on ValueRay.

Headquartered in California with operations in China and France, Amphastar also produces treatments for opioid overdose and deep vein thrombosis. Its diverse product line spans across diagnostic agents, anesthetics, and iron replacement therapies for chronic kidney disease patients.

Headlines to Watch Out For
  • BAQSIMI acquisition integration and market share growth drive proprietary product revenue
  • FDA approval timeline for generic inhalation and biosimilar pipeline impacts valuation
  • Vertical integration of API manufacturing reduces supply chain costs and improves margins
  • Primatene MIST over-the-counter sales volume dictates consistent retail cash flow performance
  • Competitive pricing pressure on generic Enoxaparin affects long-term injectable portfolio profitability
Piotroski VR‑10 (Strict) 5.5
Net Income: 79.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.04 > 1.0
NWC/Revenue: 65.12% < 20% (prev 53.40%; Δ 11.72% < -1%)
CFO/TA 0.10 > 3% & CFO 168.9m > Net Income 79.2m
Net Debt (466.9m) to EBITDA (156.0m): 2.99 < 3
Current Ratio: 3.85 > 1.5 & < 3
Outstanding Shares: last quarter (46.5m) vs 12m ago -6.88% < -2%
Gross Margin: 47.34% > 18% (prev 0.51%; Δ 4.68k% > 0.5%)
Asset Turnover: 44.01% > 50% (prev 44.78%; Δ -0.77% > 0%)
Interest Coverage Ratio: 2.85 > 6 (EBITDA TTM 156.0m / Interest Expense TTM 25.7m)
Altman Z'' 4.30
A: 0.28 (Total Current Assets 633.7m - Total Current Liabilities 164.5m) / Total Assets 1.65b
B: 0.41 (Retained Earnings 673.3m / Total Assets 1.65b)
C: 0.04 (EBIT TTM 73.4m / Avg Total Assets 1.64b)
D: 0.76 (Book Value of Equity 667.6m / Total Liabilities 874.8m)
Altman-Z'' = 4.30 = AA
Beneish M -3.05
DSRI: 1.03 (Receivables 147.8m/145.4m, Revenue 720.5m/728.3m)
GMI: 1.07 (GM 47.34% / 50.67%)
AQI: 0.92 (AQ_t 0.39 / AQ_t-1 0.42)
SGI: 0.99 (Revenue 720.5m / 728.3m)
TATA: -0.05 (NI 79.2m - CFO 168.9m) / TA 1.65b)
Beneish M = -3.05 (Cap -4..+1) = AA
What is the price of AMPH shares? As of May 23, 2026, the stock is trading at USD 18.16 with a total of 1,656,977 shares traded.
Over the past week, the price has changed by +4.97%, over one month by -14.38%, over three months by -34.08% and over the past year by -24.83%.
Is AMPH a buy, sell or hold? Amphastar P has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold AMPH.
  • StrongBuy: 2
  • Buy: 0
  • Hold: 4
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AMPH price?
Analysts Target Price 23.3 28.5%
Amphastar P (AMPH) - Fundamental Data Overview as of 21 May 2026
P/E Trailing = 10.7349
P/S = 1.0905
P/B = 1.0154
P/EG = 2.77
Revenue TTM = 720.5m USD
EBIT TTM = 73.4m USD
EBITDA TTM = 156.0m USD
Long Term Debt = 609.8m USD (from longTermDebt, last quarter)
Short Term Debt = 11.4m USD (from shortTermDebt, last quarter)
Debt = 761.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 74.9m
Net Debt = 466.9m USD (calculated: Debt 761.3m - CCE 294.4m)
Enterprise Value = 1.25b USD (785.7m + Debt 761.3m - CCE 294.4m)
Interest Coverage Ratio = 2.85 (Ebit TTM 73.4m / Interest Expense TTM 25.7m)
EV/FCF = 9.27x (Enterprise Value 1.25b / FCF TTM 135.2m)
FCF Yield = 10.79% (FCF TTM 135.2m / Enterprise Value 1.25b)
FCF Margin = 18.76% (FCF TTM 135.2m / Revenue TTM 720.5m)
Net Margin = 11.00% (Net Income TTM 79.2m / Revenue TTM 720.5m)
Gross Margin = 47.34% ((Revenue TTM 720.5m - Cost of Revenue TTM 379.4m) / Revenue TTM)
Gross Margin QoQ = 41.08% (prev 46.79%)
Tobins Q-Ratio = 0.76 (Enterprise Value 1.25b / Total Assets 1.65b)
Interest Expense / Debt = 0.86% (Interest Expense 6.55m / Debt 761.3m)
Taxrate = 36.13% (3.63m / 10.1m)
NOPAT = 46.9m (EBIT 73.4m * (1 - 36.13%))
Current Ratio = 3.85 (Total Current Assets 633.7m / Total Current Liabilities 164.5m)
Debt / Equity = 0.98 (Debt 761.3m / totalStockholderEquity, last quarter 773.4m)
Debt / EBITDA = 2.99 (Net Debt 466.9m / EBITDA 156.0m)
Debt / FCF = 3.45 (Net Debt 466.9m / FCF TTM 135.2m)
Total Stockholder Equity = 774.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.84% (Net Income 79.2m / Total Assets 1.65b)
RoE = 10.23% (Net Income TTM 79.2m / Total Stockholder Equity 774.1m)
RoCE = 5.30% (EBIT 73.4m / Capital Employed (Equity 774.1m + L.T.Debt 609.8m))
RoIC = 3.91% (NOPAT 46.9m / Invested Capital 1.20b)
WACC = 5.76% (E(785.7m)/V(1.55b) * Re(10.81%) + D(761.3m)/V(1.55b) * Rd(0.86%) * (1-Tc(0.36)))
Discount Rate = 10.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.11 | Cagr: -5.70%
[DCF] Terminal Value 88.10% ; FCFF base≈141.2m ; Y1≈167.9m ; Y5≈263.0m
[DCF] Fair Price = 163.1 (EV 7.66b - Net Debt 466.9m = Equity 7.19b / Shares 44.1m; r=6.0% [WACC]; 5y FCF grow 20.13% → 3.0% )
EPS Correlation: 19.07 | EPS CAGR: 3.07% | SUE: -3.27 | # QB: -2
Revenue Correlation: 79.35 | Revenue CAGR: 8.71% | SUE: -0.36 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.67 | Chg30d=-15.03% | Revisions=-60% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.83 | Chg30d=-11.26% | Revisions=-40% | Analysts=6
EPS current Year (2026-12-31): EPS=2.75 | Chg30d=-15.83% | Revisions=-60% | GrowthEPS=-15.3% | GrowthRev=+3.7%
EPS next Year (2027-12-31): EPS=3.28 | Chg30d=-5.29% | Revisions=-40% | GrowthEPS=+19.1% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: -60%